Intelligence · Clinical Development
Pipeline search results
Programs matching “recombinant” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 118 pipeline programs matching "recombinant" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Recombinant Interferon Alpha
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Essential Thrombocytopenia
2 trials -
Recombinant anti-PD-1 humanized monoclonal antibody injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Sarcoma, Soft Tissue
1 trial -
Recombinant human Arylsulfatase A (rhASA)
Takeda
Late Infantile Metachromatic Leukodystrophy
1 trial -
Recombinant human arylsulfatase A
Takeda
Metachromatic Leukodystrophy (MLD)
1 trial -
Recombinant human arylsulfatase A
Shire
Metachromatic Leukodystrophy (MLD)
1 trial -
Recombinant human endostatin
The First People's Hospital of Lianyungang
Stage III Non-small-Cell Lung Cancer
1 trial -
Recombinant human growth hormone
United Therapeutics Europe Ltd
Gulf War Syndrome
1 trial -
Recombinant human heparan N-sulfatase (rhHNS)
Takeda
Mucopolysaccharidosis (MPS)
1 trial -
Recombinant human heparan N-sulfatase [rhHNS]
Takeda
Sanfilippo Syndrome
1 trial -
Recombinant human hyaluronidase + immune globulin intravenous
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
Recombinant human tissue kallikrein
DiaMedica Therapeutics
Acute Ischemic Stroke
1 trial -
SSGJ-611-PED-AD-Ib/II-01
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Dermatitis, Atopic
1 trial -
activated recombinant human factor VII
Novo Nordisk A/S
Acquired Bleeding Disorder
2 trials -
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
recombinant human Angiostatin protein
CASI Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial -
recombinant human endostatin
Peking University Third Hospital
Melanoma
1 trial -
recombinant human erythropoietin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypoxic-Ischemic Encephalopathy
1 trial -
recombinant human erythropoietin (rhEpo)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Infant, Premature
1 trial -
recombinant human growth hormone
Affiliated Hospital of Jiangnan University
Phelan-McDermid Syndrome
1 trial -
recombinant humanized anti-CD25 monoclonal antibody
The First People's Hospital of Lianyungang
Transfusion Dependent Thalassemia
1 trial -
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HPV Infection
1 trial -
JSVCT098
Jiangsu Province Centers for Disease Control and Prevention
COVID-19
1 trial -
PEGylated recombinant candida urate oxidase
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Gout
1 trial -
PEGylated recombinant human hyaluronidase PH20
HALOZYME THERAPEUTICS, INC.
Non-small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.